{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-004746","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.550181+00:00","generated_at":"2026-05-23T15:25:49.058709+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Coherus completes UDENYCA divestiture to Intas for $483.4M upfront; pivots to oncology","bullets":["Closed sale of UDENYCA franchise on April 11, 2025; receives $483.4M cash including $118.4M for inventory.","Eligible for two milestone payments up to $75M total if net sales thresholds met through 2027.","Pro forma cash balance post-close ~$250M; cash runway extended over two years into 2027.","Plans to use proceeds to repurchase $230M of 1.500% Convertible Notes due 2026.","Focus shifts to LOQTORZI, casdozokitug, and CHS-114 novel oncology pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-004746","json":"https://secwatch.observer/filing/0001558370-25-004746.json","markdown":"https://secwatch.observer/filing/0001558370-25-004746.md","text":"https://secwatch.observer/filing/0001558370-25-004746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/0001558370-25-004746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/chrs-20250411x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:25:49.058709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d6de1cfe5e15fe58327ad6c5c95f6e818a72817d","claim":"Coherus Oncology, Inc. completed a disposition involving Intas Pharmaceuticals Ltd. for $483.4 million in cash (closed 2025-04-11).","evidence_excerpt":"On April 11, 2025 (the “Closing Date”), the Company completed the divestiture of the Business (the “UDENYCA Disposition”) to Intas for upfront, all-cash consideration of $483.4 million in cash, inclusive of $118.4 million for UDENYCA product inventory.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025004746/0001558370-25-004746-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Intas Pharmaceuticals Ltd."},{"label":"Consideration","value":"$483.4 million in cash"},{"label":"Closing","value":"2025-04-11"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}